Compare MTG & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTG | FOLD |
|---|---|---|
| Founded | 1957 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.5B |
| IPO Year | 2008 | 2006 |
| Metric | MTG | FOLD |
|---|---|---|
| Price | $26.05 | $14.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $28.50 | $27.25 |
| AVG Volume (30 Days) | 1.6M | ★ 2.5M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.06% | N/A |
| EPS Growth | 8.65 | ★ 50.00 |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $1,213,636,000.00 | N/A |
| Revenue This Year | $2.50 | $20.50 |
| Revenue Next Year | $1.77 | $18.59 |
| P/E Ratio | $33.96 | ★ N/A |
| Revenue Growth | ★ 0.49 | N/A |
| 52 Week Low | $24.69 | $5.66 |
| 52 Week High | $29.97 | $14.50 |
| Indicator | MTG | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 74.18 |
| Support Level | $25.57 | $14.21 |
| Resistance Level | $27.14 | N/A |
| Average True Range (ATR) | 0.47 | 0.02 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 86.34 | 100.00 |
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection account for close to the majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia, and New York.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.